Table 2.
Prevalence of comorbidities in patients of age ≥ 18 years
| SARS-CoV-2 | Influenza A | RSV | P value | |
|---|---|---|---|---|
| n | 430 | 163 | 35 | |
| Hypertension | 267 (62.1%) | 96 (58.9%) | 25 (71.4%) | 0.385 |
| Peripheral artery disease (PAD) | 33 (7.7%) | 8 (4.9%) | 6 (17.1%) | 0.048 |
| Heart failure (HF) | 83 (19.3%) | 35 (21.5%) | 17 (48.6%) | < 0.001 |
| Coronary artery disease (CAD) | 103 (24.0%) | 32 (19.6%) | 7 (20.0%) | 0.529 |
| Diabetes mellitus Type 2 | 120 (27.9%) | 42 (25.8%) | 8 (22.9%) | 0.774 |
| COPD | 60 (14.0%) | 32 (19.6%) | 9 (25.7%) | 0.068 |
| Asthma | 19 (4.4%) | 14 (8.6%) | 5 (14.3%) | 0.018 |
| Other lung disease* | 134 (31.2%) | 52 (31.9%) | 14 (40.0%) | 0.565 |
| Chronic kidney disease (CKD) | 133 (30.9%) | 44 (27.0%) | 6 (17.1%) | 0.180 |
| Active malignant disease** | 97 (22.6%) | 28 (17.2%) | 7 (20.0%) | 0.354 |
| Rheumatic disease | 20 (4.7%) | 5 (3.1%) | 2 (5.7%) | 0.612 |
| Depression | 51 (11.9%) | 12 (7.4%) | 2 (5.7%) | 0.217 |
| Dementia | 71 (16.5%) | 10 (6.1%) | 5 (14.3%) | 0.002 |
| State of Immunosuppression | 21 (4.9%) | 19 (11.7%) | 3 (8.6%) | 0.012 |
| Number of Comorbidities*** | 3 (2; 4) | 2 (1; 4) | 3 (2; 4) | 0.151 |
Numbers and percentages are shown, for the sum of comorbidities median values and quartiles *except malignant lung disease, **within the last 5 years, *** sum of comorbidities from this list
Statistical comparisons between the infection groups were performed with the exact test according to Fisher-Freeman-Halton, for the sum using the Kruskal–Wallis test